Auckland-based medical device company Nexus6 has secured $3m from Australia-based life sciences investment firm BioScience Managers.
Nexus6 will use the capital to support international expansion of its asthma monitoring technology and significantly increase its sales and marketing capabilities.
The technology, Smartinhaler, enables physicians to remotely monitor real life use of asthma treatment regimes and ensure that asthma sufferers are adhering to the optimal treatment program for their condition.
BioScience Managers managing director Jeremy Curnock Cook said in addition to better patient outcomes, Nexus6's technology minimizes wastage and costs of treatment, by ensuring that patients take only what they need and when they need it.
"Nexus6 also provides a unique supporting technology for asthma clinical trials," Cook added.
In addition to $3m, Nexus6 has secured up to $2m from its existing investors including leading NZ venture firm K1W1.
BioScience Managers chief investment officer Matt McNamara said the healthcare sector is increasing at a global macroeconomic level, with both the cost and the effectiveness of healthcare solutions coming under increasing scrutiny.
"We believe there is a significant opportunity in the investment in and consolidation of medical technologies from around the world to enable those companies better access to international markets and economies of scale across synergistic businesses," McNamara added.
Nexus6 also marks BioScience Managers' second investment from its Asia Pacific Healthcare Fund II.
